[Transfer] The new "weight loss pill" sells out of stock?A number of pharmaceutical companies accelerate the layout

[Transfer] The new "weight loss pill" sells out of stock? A number of pharmaceutical companies accelerate the layout

Source: Sai Bailan/Mu Zhi

01

Smegugu peptide sells out of stock

Recently, according to media reports, some of the weight -loss pharmacies who were used for weight loss for weight loss drugs, Meglugin, had sold out stock in some regions, which caused the industry's attention.

According to public information, the Smegugu peptide injection is a new type of long-acting long-acting pancreatic hyperglycean-1 (GLP-1) analogs developed by Novo Nord. In April 2021 It is used to treat the risk of cardiovascular adverse incidents in patients with type 2 diabetes and reducing T2DM combined with cardiovascular disease.

On the official website of Nuo and Nord, some doses of Smeglugan injection have shown the shortage of goods. Novo Nord wrote in the statement: "The demand of Smeglugan peptide has exceeded the previously estimated market demand. At the same time, after the product was launched, there was a problem with the CMO collaborated by Nond and Nord. As a result, the supply is shortage. "

As for when the supply is resumed, Novo said: "All efforts will be done to achieve the commitment to fully restore all dose of supply in the second half of 2022, but it is not currently determined by the specific date."

Although Novo Nord's announcement did not directly give the reason for the surge in demand, according to industry analysts, the probability is related to its recognized "weight loss effect".

It can be seen that the demand for weight loss products in the market is extremely considerable.

02

The weight loss market has four smokes, and many pharmaceutical companies have accelerated the layout

"Report on the Nutrition and Chronic Diseases of Chinese Residents (2020)" shows that more than 50%of adult residents in my country are overweight or obese, and children and adolescents under the age of 17 and under 6 years old are overweight/obesity rates reached 19%and 10.4%respectively; 18 The obesity rate of residents over the age of 16.4%, an overweight rate of 34.3%. At present, the weight control of overweight and obese patients has become an urgent clinical needs. It is expected that the compliance market for weight loss pills in 2025 is expected to exceed 12 billion yuan.

However, according to the "Principles of the Clinical Test Technical Guidance of Drug Control Drugs" released by CDE, only one drug in my country is currently approved by Olisc Capsules for treatment of obesity or overweight patients, compliant, safe, and effective weight control Drugs have huge clinical needs that have not been met.

In addition to Oli Simer and Smeglugan, it is also favorable to perform well in this field. Because the GLP-1 drug represented by Lilanton peptides presents a significant treatment effect in weight loss, it has the effects of weight loss, sugar reduction and cardiovascular benefit. The target has increased rapidly in recent years.

On June 23, East China Pharmaceutical announced a strategic cooperation with the Middle East company Julphar. JulPhar will obtain two indications: diabetes and weight loss products in its Licolaptide injection products in the UAE, Saudi Arabia, Egypt, Kuwait, Barin and other Middle East and the Middle East The development, production and commercialization of 17 countries in North Africa.

On July 13, East China Pharmaceutical Announcement stated that its wholly -owned subsidiary Hangzhou China and the United States East China received the "Acceptance Notice" issued by the State Drug Administration, which was applied for obesity or overweight by the Leralu peptide injection reported by East China, China and the United States. Application for the listing permit for indications was accepted.

A pharmaceutical market researcher told the author: "A series of actions in East China Pharmaceutical broke the rigid situation in the past, and the glucose and weight loss market may usher in new changes."

In the three drugs of Oli Sett, Lichel Peptide, and Smeglugin, it is currently included in East China Medicine mentioned above, as well as Haizheng Pharmaceuticals, Shanghai Renhui Biology, Aimei, and Li More than 40 companies including Zhu Group are layout. Whoever can get the lead will get the richer market return.

03

What is the safety of "weight loss new stars" selling out of stock?

On June 4, 2021, Simeng Gulu peptide injection (2.4 mg, once a week) was officially approved by the US FDA for chronic weight management for obesity or overweight adults, which marks the treatment of Smegugu peptide. Diabetes new star official cross -border weight loss field.

Smegutlin peptide is a high-blood glucose-1 receptor agonist, that is, the GLP-1 receptor agonist. It mainly acts in islet beta cells and promotes the synthesis and secretion of insulin; it can also act on islet α cells, inhibit the release of hyperglycemia, reduce the release of liver sugar; enhance the sensitivity of insulin The sense of satiety acts on the hypothalamus to suppress appetite, reduce weight, and achieve the effect of reducing sugar through these functions.

The results of the STEP 3A clinical trial published by the New England Medical Magazine (Nejm) showed that the effects of Smegugu peptid peptides have outstanding weight loss effects, and in the test in non -diabetes, the project involved more than 4500 cases without type 2 without type 2. Obesity or overweight adult patients of diabetes, patients with obesity treated by Smeglugan peptide were alleviated by an average weight of 17-18%within 68 weeks. Tests showed safety and good tolerance.

But it is important to emphasize that not everyone can use Smeglugin to lose weight. The applicable population approved by the US FDA is: (1) patients with adult group weight index (BMI) ≥30kg/m2; (2) accompanied by at least one disease -related disease (such as hypertension, type 2 diabetes or high or high Cholesterol) adult overweight groups (BMI ≥ 27kg/m2).

In terms of dosage, the US FDA pointed out in the announcement that it needs to be gradually increased to 2.4mg per week during 16 to 20 weeks to reduce gastrointestinal side effects.In terms of combined medication, it should not be jointly used with other GLP-1 receptor agonists or other products for weight loss (including prescription drugs, non-prescription medicines or herbs).In addition, although many tests have proved that Smeglugan peptide is highly safe, but there is no absolute thing in everything, the most common adverse reactions of the medicine are: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, digestion, digestionBad, dizziness, abdominal distension, qi, gastrointestinal qi (qi accumulation), gastroenteritis and gastroesophageal reflux disease.

In the future, the related pharmaceutical companies will focus on the product of "weight loss" as the introduction of products. These issues are worthy of attention.

Disclaimer: This article is the content of Yaozhi.com, and the copyright of the pictures and text belongs to the original author. The purpose of reprinting is to pass more information, which does not represent the viewpoint of this platform.If the content, copyright and other issues are involved in the work, please leave a message on this platform, and we will delete it as soon as possible.

- END -